Research Article
TREM2 as a Potential Immune-Related Biomarker of Prognosis in Patients with Skin Cutaneous Melanoma Microenvironment
Table 1
SKCM patient’s clinical characteristics in the present study.
| | Characteristic | Levels | Overall |
| | | 468 |
| | Age, (%) | ≤60 | 249 (54.1%) | | >60 | 211 (45.9%) |
| | Gender, (%) | Female | 179 (38.2%) | | Male | 289 (61.8%) |
| | Race, (%) | Asian | 12 (2.6%) | | Black or African American | 1 (0.2%) | | White | 445 (97.2%) |
| | BMI, (%) | ≤25 | 84 (33.7%) | | >25 | 165 (66.3%) |
| | T stage, (%) | T1 | 41 (11.4%) | | T2 | 78 (21.6%) | | T3 | 90 (24.9%) | | T4 | 152 (42.1%) |
| | N stage, (%) | N0 | 234 (56.9%) | | N1 | 74 (18%) | | N2 | 49 (11.9%) | | N3 | 54 (13.1%) |
| | M stage, (%) | M0 | 416 (94.5%) | | M1 | 24 (5.5%) |
| | Pathologic stage, (%) | Stage I | 76 (18.6%) | | Stage II | 140 (34.2%) | | Stage III | 170 (41.6%) | | Stage IV | 23 (5.6%) |
| | Radiation therapy, (%) | No | 381 (82.6%) | | Yes | 80 (17.4%) |
| | Age, median (IQR) | | 58 (48, 71) |
|
|
